B‐lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology

Soslow, Robert A.; Baergen, Rebecca N.; Warnke, Roger A.

doi:10.1002/(sici)1097-0142(19990615)85:12<2648::aid-cncr22>3.3.co;2-i

Cited by 22 publications

(28 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our series, immunophenotype and clinical stage did not have a significant effect, although survival was slightly better in patients with B-rather than T-LL, as reported previously [27,28], and in patients with stage I/II (85%) rather than stage III/IV (62%) disease. Given that, in patients with ALL, MRD is the best available means to predict relapse and to select high-risk patients for allogeneic SCT [15], we elected to investigate the use of this parameter in adult LL.…”

Section: Discussionmentioning

confidence: 99%

Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma

et al. 2011

View full text Add to dashboard Cite

The therapeutic role of mediastinal radiotherapy and stem cell transplantation (SCT) in lymphoblastic lymphoma (LL) remains controversial. In a risk-oriented design, we adopted a flexible treatment program in which (1) patients with persistent mediastinal abnormality, evaluated by post-induction computed chest tomography, received mediastinal irradiation; and (2) those with persistence of minimal residual disease (MRD), evaluated by MRD analysis of the bone marrow, underwent SCT.Twenty-eight out of 30 patients (T-lineage, n=24; Blineage, n=6) achieved a complete response. Of 21 patients with mediastinal mass, 13 (62%) achieved a complete response after chemotherapy alone, while 6 (28.5%) required additional irradiation. Eleven patients were evaluated for MRD: 6 were negative and 5 positive. On the basis of MRD findings and clinical risk characteristics, 14 patients underwent SCT, 13 received maintenance chemotherapy, and 1 had local radiotherapy. Five patients Sergio Cortelazzo and Renato Bassan contributed equally to the manuscript.Electronic supplementary material The online version of this article

show abstract

Section: Discussionmentioning

confidence: 99%

Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Even though the cytological and histological features of LBL and ALL are very similar, these two diseases do differ, mostly by the immunophenotypic origin of the clonal proliferation since 80% of LBL blasts have the T-cell phenotype. 1 Therapeutic studies on T-LBL/ALL are scarce 2 and treatments of the type used for non-Hodgkin's lymphoma (NHL) have given disappointing results.…”

mentioning

confidence: 99%

Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial

Hunault

Truchan-Graczyk²,

Caillot³

et al. 2007

Haematologica

View full text Add to dashboard Cite

“…Recent study also reported that B-LBL is associated with a relatively favourable prognosis, compared to T-LBL. 7,10 In conclusion, we described a case of B-LBL with cutaneous involvement occurring in an old man. Because B-LBL, especially its cutaneous involvement, is rare, it has hardly reported in the dermatologic literature.…”

Section: Case Reportmentioning

confidence: 98%

“…B-LBL is composed of immature lymphocytes that demonstrate lymphoblastic morphology and express TdT, CD99, human leucocyte antigen (HLA)-DR, and tend to express B-cell markers, such as CD79a, CD19, CD20, CD22 and CD10, and rarely express cytoplasmic m heavy chains without surface immunoglobulin. 7 Recent studies have reported that CD179a and CD179b may be important markers for the immunophenotypic diagnosis of B-LBL. 8 Precursor T-cell LBL (T-LBL) patients tend to present at an older age than B-LBL patients.…”

Section: Case Reportmentioning

confidence: 99%

Precursor B‐cell lymphoblastic lymphoma involving the skin

Kim

Lee

2006

J Cutan Pathol

View full text Add to dashboard Cite

Precursor B-cell lymphoblastic lymphoma (B-LBL) is a rare neoplasm composed of immature lymphocytes that demonstrate lymphoblastic morphology and express precursor and B-cell marker. It usually affects people of younger age group and causes multiple nodules on the head and neck area. The neoplasm is rare in old age. We report a case of B-LBL occurring in a 65-year-old man. He presented with multiple skin nodules on the scalp, the neck and the arm for 2 months. Histopathologic examination demonstrated diffuse dermal and subcutaneous monotonous infiltrates of medium-sized lymphoid cells with starry-sky pattern. Immunohistochemical study showed that the lymphoid cells of infiltrate showed precursor B-cell type. The patient has received combination chemotherapy three times and is being followed-up at the outpatient clinic. Lymphoblastic lymphoma (LBL) is the most aggressive, high-grade form of non-Hodgkin's lymphoma (NHL). It accounts for only 5% of all NHL. Moreover, cutaneous LBL comprises a smaller percentage (<20%) of all LBL cases at the time of presentation.

show abstract

B‐lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology

Cited by 22 publications

References 12 publications

Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma

Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma

Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial

Precursor B‐cell lymphoblastic lymphoma involving the skin

Contact Info

Product

Resources

About